Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
3.
Br J Haematol ; 196(4): 892-901, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34761389

RESUMEN

Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.


Asunto(s)
Antígenos CD20/inmunología , Antineoplásicos Inmunológicos/uso terapéutico , COVID-19/complicaciones , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/tratamiento farmacológico , Adulto , Antineoplásicos Inmunológicos/efectos adversos , COVID-19/etiología , COVID-19/inmunología , Femenino , Neoplasias Hematológicas/inmunología , Humanos , Leucemia/complicaciones , Leucemia/tratamiento farmacológico , Leucemia/inmunología , Masculino , Mieloma Múltiple/complicaciones , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/inmunología , Estudios Prospectivos , Factores de Riesgo
4.
Blood Coagul Fibrinolysis ; 33(2): 130-133, 2022 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-34799506

RESUMEN

We describe a case of a patient with multiple myeloma with initial presentation simulating a bleeding disorder. Detailed coagulation work-up showed hypodysfibrinogenaemia along with a platelet function defect consistent with acquired Bernard-Soulier syndrome (BSS). Multiple plasma exchanges led to significant improvement in his bleeding symptoms. To the best of our knowledge, this is the first described case of simultaneous presentation of hypodysfibrinogenaemia and BSS secondary to multiple myeloma.


Asunto(s)
Síndrome de Bernard-Soulier , Mieloma Múltiple , Síndrome de Bernard-Soulier/complicaciones , Coagulación Sanguínea , Hemorragia , Humanos , Mieloma Múltiple/complicaciones
5.
EJHaem ; 2(4): 785-788, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34909765

RESUMEN

The COVID-19 pandemic has disturbed medical training. Haematology registrars were surveyed using SurveyMonkey. Eighty-nine out of 269 (24.9%) responded. Reported stressors included concerns about transmitting the infection, disruption of leave, inferior patient outcomes, survivors' guilt and interruption of career progression. Only 31.2% felt ready to progress to the next training stage. Reported causes of lack of training were disruption of clinics and training days and utilisation of telephone consultations. Several stressors negatively impacted haematology registrars' well-being, training and progression. More emphasis on psychological support, outpatient clinic work and e-learning is needed.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...